Gland Pharma Limited — Board Meeting, 03-02-2025: Outcome of Board Meeting

The Board of Directors of Gland Pharma Limited has approved the financial results for the quarter and nine months ending December 31, 2024. Total revenue for Q3 FY25 is reported at ₹13,841 million, reflecting a decrease of 10% year-on-year. However, EBITDA rose to ₹3,600 million, demonstrating a 1% increase from the previous year, with an improved EBITDA margin of 26%. The company achieved a profit after tax (PAT) of ₹2,047 million, a 7% year-on-year growth. Additionally, the Board appointed M/s. Grant Thornton Bharat LLP as the Internal Auditors for the financial year 2025-26.